The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

An Update on Avelumab as Monotherapy for Urothelial Carcinoma

Andrea Apolo, MD
Published Online: 5:05 PM, Mon September 11, 2017

Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses the recent updates presented at the 2017 ESMO Annual Congress regarding avelumab (Bavencio) monotherapy for patients with urothelial carcinoma.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.